The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Gustav Smith, MD, PhD

Gustav Smith

Associate professor

Gustav Smith, MD, PhD

A pharmacodynamic comparison of 5 anti-platelet protocols in patients with ST-elevation myocardial infarction undergoing primary PCI.

Author

  • Sasha Koul
  • Pontus Andell
  • Andreas Martinsson
  • Gustav Smith
  • Fredrik Scherstén
  • Jan Harnek
  • Matthias Götberg
  • Eva Norström
  • Sven Björnsson
  • David Erlinge

Summary, in English

Despite advances in anti-platelet treatments, there still exists an early increase in both ischemic as well as bleeding events following primary PCI in patients with ST-elevation myocardial infarction (STEMI). Platelet inhibition data of different anti-platelet treatments in the acute phase of a myocardial infarction might offer some insight into these problems. The aim of this study was to evaluate the pharmacodynamic profile of 5 different anti-platelet treatments in the acute phase of STEMI in patients undergoing primary PCI.

Department/s

  • Cardiology
  • Division of Hematology and Transfusion Medicine
  • Clinical Chemistry, Malmö
  • EXODIAB: Excellence of Diabetes Research in Sweden
  • EpiHealth: Epidemiology for Health

Publishing year

2014

Language

English

Publication/Series

BMC Cardiovascular Disorders

Volume

14

Document type

Journal article

Publisher

BioMed Central (BMC)

Topic

  • Cardiac and Cardiovascular Systems

Status

Published

Research group

  • Clinical Chemistry, Malmö

ISBN/ISSN/Other

  • ISSN: 1471-2261